The efficacy advantage of evolocumab (AMG 145) dosed at 140Â mg every 2Â weeks versus 420Â mg every 4Â weeks in patients with hypercholesterolemia: Evidence from a meta-analysis

Evolocumab administered at 140 mg Q2W was more effective than the 420 mg Q4W dosage at lowering lipid concentrations, especially in patients who concomitantly received stable statin therapy.